journal article·2019-12-18Open access

Supramolecular Insights into Domino Effects of Ag@ZnO-Induced Oxidative Stress in Melanoma Cancer Cells

Behnaz Ghaemi, Arfa Moshiri, Inge K. Herrmann, Mohammad Javad Hajipour, Peter Wick, Amir Amani, Sharmin Kharrazi

ACS Applied Materials & Interfaces· Volume 11· Issue 50

Abstract

Recent studies suggest that cancer cell death accompanied by organelle dysfunction might be a promising approach for cancer therapy. The Golgi apparatus has a key role in cell function and may initiate signaling pathways to mitigate stress and, if irreparable, start apoptosis. It has been shown that Golgi disassembly and fragmentation under oxidative stress act as indicators for stress-mediated cell death pathways through cell cycle arrest in the G2/M phase. The present study shows that UV-induced reactive oxygen species (ROS) generation by Ag@ZnO nanoparticles (NPs) transform the Golgi structures from compressed perinuclear ribbons into detached vesicle-like structures distributed in the entire cytoplasm of melanoma cells. This study also demonstrates that Ag@ZnO NP-induced Golgi fragmentation cooccurs with G2 block of cell cycle progression, preventing cells from entering the mitosis phase. Additionally, the increased intracellular ROS production triggered by Ag@ZnO NPs upon UV exposure promoted autophagy. Taken together, Ag@ZnO NPs induce stress-related Golgi fragmentation and autophagy, finally leading to melanoma cell apoptosis. Intracellular oxidative stress generated by Ag@ZnO NPs upon UV irradiation may thus represent a targeted approach to induce cancer cell death through organelle destruction in melanoma cells, while fibroblast cells remained largely unaffected.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Free Radicals and Antioxidants · Metal-Organic Frameworks: Synthesis and Applications · Advanced Nanomaterials in Catalysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Medical Nanotechnology, School of Advanced Technologies in Medicine (SATiM), Tehran University of Medical Sciences, 1417755469 Tehran, Iran

Laboratory for Particles-Biology Interactions, Swiss Federal Laboratories for Material Science and Technology (Empa), 9014 St. Gallen, Switzerland

Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, 1985717413 Tehran, Iran

Laboratory of Experimental Therapies in Oncology, IRCCS Instituto Giannina Gaslini, 16147 Genova, Italy

Precision Health Program, Michigan State University, East Lansing, Michigan 48824, United States

Natural Products and Medicinal Plants Research Center, North Khorasan University of Medical Sciences, 9414975516 Bojnurd, Iran

Funding

Tehran University of Medical Sciences and Health Services

References (70)

Show source-provided references
1. 10.1016/j.ijcard.2010.03.00310.1016/j.ijcard.2010.03.003 ↗
2. 10.1038/nrc195010.1038/nrc1950 ↗
3. 10.1007/s10549-010-1077-710.1007/s10549-010-1077-7 ↗
4. 10.1038/nnano.2007.38710.1038/nnano.2007.387 ↗
5. 10.1039/C4RA10862K10.1039/C4RA10862K ↗
6. 10.1016/j.biomaterials.2011.10.08010.1016/j.biomaterials.2011.10.080 ↗
7. 10.1016/j.biomaterials.2016.09.00510.1016/j.biomaterials.2016.09.005 ↗
8. 10.1016/j.biomaterials.2009.08.00810.1016/j.biomaterials.2009.08.008 ↗
9. 10.1016/j.biomaterials.2010.04.01410.1016/j.biomaterials.2010.04.014 ↗
10. 10.1166/jbn.2013.159310.1166/jbn.2013.1593 ↗
11. 10.1038/nrd280310.1038/nrd2803 ↗
12. 10.1038/cdd.2014.15010.1038/cdd.2014.150 ↗
13. 10.1016/j.pneurobio.2013.04.00410.1016/j.pneurobio.2013.04.004 ↗
14. 10.3389/fnins.2015.0042110.3389/fnins.2015.00421 ↗
15. 10.1016/j.cell.2013.12.02310.1016/j.cell.2013.12.023 ↗
16. 10.1016/j.bbamcr.2005.03.00210.1016/j.bbamcr.2005.03.002 ↗
17. 10.1038/ncb286510.1038/ncb2865 ↗
18. 10.1073/pnas.161084411310.1073/pnas.1610844113 ↗
19. 10.1016/S0092-8674(02)00720-110.1016/S0092-8674(02)00720-1 ↗
20. 10.1002/iub.105410.1002/iub.1054 ↗
21. 10.1016/j.ccr.2006.08.01510.1016/j.ccr.2006.08.015 ↗
22. 10.1097/WOX.0b013e318243961310.1097/WOX.0b013e3182439613 ↗
23. 10.1007/s00432-017-2464-910.1007/s00432-017-2464-9 ↗
24. 10.1002/anie.20170118110.1002/anie.201701181 ↗
25. 10.1021/acsami.8b0382210.1021/acsami.8b03822 ↗
26. 10.1002/jlb.55.2.25310.1002/jlb.55.2.253 ↗
27. 10.1073/pnas.161668311410.1073/pnas.1616683114 ↗
28. 10.1021/acsami.8b0382210.1021/acsami.8b03822 ↗
29. 10.1002/smll.20180410510.1002/smll.201804105 ↗
30. 10.1021/nl070363y10.1021/nl070363y ↗
31. 10.1021/cr300262710.1021/cr3002627 ↗
32. 10.1007/s12668-018-0538-z10.1007/s12668-018-0538-z ↗
33. 10.1016/j.pdpdt.2018.10.01210.1016/j.pdpdt.2018.10.012 ↗
34. Manoto, S. L.; Oluwole, D. O.; Malabi, R.; Maphanga, C.; Ombinda-Lemboumba, S.; Nyokong, T.; Mthunzi-Kufa, P. In Phototoxic Effects of Free Phthalocyanine and Phthalocyanine Conjugated to Gold Nanoparticles for Targeted Photodynamic Therapy of Melanoma Cancer, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XXVI; International Society for Optics and Photonics, 2017; p 100470D.10.1117/12.2252682 ↗
35. 10.1002/jbio.20170007710.1002/jbio.201700077 ↗
36. 10.1080/17435390.2019.157037310.1080/17435390.2019.1570373 ↗
37. 10.4161/oxim.3.4.1285810.4161/oxim.3.4.12858 ↗
38. 10.1088/2053-1591/aadce910.1088/2053-1591/aadce9 ↗
39. 10.1021/acsnano.7b0621210.1021/acsnano.7b06212 ↗
40. 10.1021/nn503450t10.1021/nn503450t ↗
41. 10.1016/j.freeradbiomed.2016.11.04810.1016/j.freeradbiomed.2016.11.048 ↗
42. 10.1002/anie.20171202710.1002/anie.201712027 ↗
43. 10.1021/jacs.9b0345710.1021/jacs.9b03457 ↗
44. 10.1016/j.ajme.2017.09.00110.1016/j.ajme.2017.09.001 ↗
45. 10.1016/j.cbpc.2016.02.00810.1016/j.cbpc.2016.02.008 ↗
46. 10.3390/ijms1801012010.3390/ijms18010120 ↗
47. Beams H. · 1968 · 209
48. 10.1091/mbc.e04-07-059410.1091/mbc.e04-07-0594 ↗
49. 10.1038/s42003-018-0212-610.1038/s42003-018-0212-6 ↗
50. 10.1083/jcb.131.6.171510.1083/jcb.131.6.1715 ↗
51. 10.1093/emboj/18.18.494910.1093/emboj/18.18.4949 ↗
52. 10.1111/j.1600-0854.2007.00542.x10.1111/j.1600-0854.2007.00542.x ↗
53. 10.1038/sj.emboj.760056910.1038/sj.emboj.7600569 ↗
54. 10.1016/j.cell.2004.11.04610.1016/j.cell.2004.11.046 ↗
55. 10.1016/j.cell.2011.10.02610.1016/j.cell.2011.10.026 ↗
56. 10.1158/0008-5472.CAN-07-616310.1158/0008-5472.CAN-07-6163 ↗
57. 10.1242/jcs.21198710.1242/jcs.211987 ↗
58. 10.1038/sj.cdd.440175110.1038/sj.cdd.4401751 ↗
59. 10.1016/j.ceb.2009.11.01510.1016/j.ceb.2009.11.015 ↗
60. 10.1038/nrc.2016.13810.1038/nrc.2016.138 ↗
61. 10.1242/jcs.16487110.1242/jcs.164871 ↗
62. 10.3390/genes810028110.3390/genes8100281 ↗
63. 10.1002/tox.2187910.1002/tox.21879 ↗
64. 10.1002/em.2192510.1002/em.21925 ↗
65. 10.1016/j.tiv.2017.02.01410.1016/j.tiv.2017.02.014 ↗
66. 10.1200/JCO.2005.03.768910.1200/JCO.2005.03.7689 ↗
67. 10.1073/pnas.111520110910.1073/pnas.1115201109 ↗
68. 10.1074/jbc.M50244220010.1074/jbc.M502442200 ↗
69. 10.18632/oncotarget.580710.18632/oncotarget.5807 ↗
70. 10.1080/15384101.2018.149123610.1080/15384101.2018.1491236 ↗